Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Phase 2 Terminated 2 enrolled University of California, San Francisco GlaxoSmithKline · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a certain type of skin cancer (BRAFV600E melanoma) and brain metastases (tumors that have spread to the brain).

Timeline

Start: 2013-04
Primary completion: 2016-01
Completion: 2016-01

Publications

Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, Prabhu RS, Khan MK. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res. 2016 Aug;26(4):387-94. doi: 10.1097/CMR.0000000000000268.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabrafenib	Small molecule	150 mg	Oral
Subject	Trametinib	Small molecule	2 mg	Oral

Indications

No indication recorded.